{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T13:03:12Z","timestamp":1785762192278,"version":"3.56.0"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Contrast-induced acute kidney injury (CI-AKI) remains a significant complication in patients with type 2 diabetes mellitus (T2DM) and renal insufficiency undergoing percutaneous coronary intervention (PCI). Many studies have shown that sodium-glucose cotransporter-2 inhibitors (SGLT2i) can improve cardiovascular and renal outcomes in T2DM patients. And chronic administration of SGLT2i has been shown to reduce the risk of CIAKI after PCI in patients with T2DM. However, the impact of short-term SGLT2i administration on the incidence of CIAKI after PCI in T2DM patients with renal insufficiency remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate the impact of short-term (&amp;lt;2\u202fweeks) administration of dapagliflozin on CIAKI in patients with T2DM and renal insufficiency undergoing PCI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study included patients with T2DM and renal insufficiency who underwent PCI in our hospital, from January to December 2024. The patients were divided into a short-term dapagliflozin group and a control group. Renal function was recorded before PCI, as well as at 48\u202fh and 1\u202fweek post-PCI. The primary endpoint was the incidence of CIAKI after PCI in both groups. The secondary endpoints included changes in renal function at 48\u202fh and 1\u202fweek post-PCI, as well as the occurrence of major adverse cardiovascular events (MACE) during the 3-month follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      (1) A total of 354 patients with T2DM and renal insufficiency underwent PCI were included in this study, with 183 patients in the short-term dapagliflozin group and 171 patients in the control group. The median duration of short-term dapagliflozin administration before PCI was 3 (2, 6) days, with an average duration of 3.56\u202f\u00b1\u202f1.62\u202fdays. (2) The incidence of CIAKI was higher in the short-term dapagliflozin group (14.2%) compared to the control group (7.0%) (\n                      <jats:italic>\n                        \u03c7\n                        <jats:sup>2<\/jats:sup>\n                      <\/jats:italic>\n                      \u202f=\u202f4.769,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.029). Logistic regression analysis indicated that short-term dapagliflozin administration before PCI was associated with an increased risk of CIAKI (OR\u202f=\u202f2.308, 95%CI: 1.002\u20135.314,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.049). (3) During the 3-month follow-up after PCI, Log-rank test showed no significant difference in the incidence of MACE between the two groups (Log-rank\n                      <jats:italic>\n                        \u03c7\n                        <jats:sup>2<\/jats:sup>\n                      <\/jats:italic>\n                      \u202f=\u202f0.851,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.356). (4) Cox regression analysis revealed that CIAKI significantly affected the short-term prognosis of T2DM patients with renal insufficiency after PCI (HR\u202f=\u202f3.025, 95%CI: 1.246\u20137.343,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.014), whereas dapagliflozin did not significantly improve the short-term prognosis of these patients after PCI (HR\u202f=\u202f1.024, 95% CI: 0.967\u20131.084,\n                      <jats:italic>p\u202f=<\/jats:italic>\n                      0.415).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Short-term (&amp;lt;2\u202fweeks) dapagliflozin administration may increase the risk of CIAKI in T2DM patients with renal insufficiency undergoing PCI. It is recommended to avoid initiating dapagliflozin in high-risk CIAKI patients prior to PCI.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2025.1744473","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T05:25:18Z","timestamp":1765776318000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["The impact of short-term administration of dapagliflozin on contrast-induced acute kidney injury in patients with type 2 diabetes and renal insufficiency undergoing percutaneous coronary intervention"],"prefix":"10.3389","volume":"12","author":[{"given":"Shicheng","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiufeng","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manxi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naikuan","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"239","DOI":"10.4103\/hm.HM-D-24-00027","article-title":"Effects of meditation and breathing therapy on anxiety improvement before and after percutaneous coronary intervention in patients with coronary artery disease: a prospective cohort study","volume":"8","author":"Yang","year":"2024","journal-title":"Heart Mind"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1177\/00033197231201931","article-title":"Comparative evaluation of intermountain risk score with Mehran risk score for risk estimation of contrast-induced nephropathy and short-term mortality in ST-segment elevation myocardial infarction patients","volume":"76","author":"Toprak","year":"2025","journal-title":"Angiology"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1177\/00033197241233771","article-title":"Impact of contrast-associated acute kidney injury on one-year outcomes in very elderly STEMI patients: insights from a multicenter registry in northern Italy","volume":"76","author":"Ruzzarin","year":"2025","journal-title":"Angiology"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1574693","DOI":"10.3389\/fmed.2025.1574693","article-title":"Application of SGLT-2 inhibitors in non-diabetic CKD: mechanisms, efficacy, and safety","volume":"12","author":"Zhang","year":"2025","journal-title":"Front Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1527972","DOI":"10.3389\/fphar.2025.1527972","article-title":"Time-varying cost-effectiveness analysis of sodium-glucose cotransporter-2 inhibitors in Chinese patients with heart failure and reduced ejection fraction: a microsimulation of the real-world population","volume":"16","author":"Zou","year":"2025","journal-title":"Front Pharmacol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"e0295059","DOI":"10.1371\/journal.pone.0295059","article-title":"The effect of sodium-glucose cotransporter 2 inhibitors in patients with chronic kidney disease with or without type 2 diabetes mellitus on cardiovascular and renal outcomes: a systematic review and meta-analysis","volume":"18","author":"Reyes-Farias","year":"2023","journal-title":"PLoS One"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1007\/s00125-024-06257-7","article-title":"Effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular and renal outcomes in people with diabetes and advanced chronic kidney disease","volume":"67","author":"Lin","year":"2024","journal-title":"Diabetologia"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1307715","DOI":"10.3389\/fendo.2023.1307715","article-title":"SGLT-2 inhibitors and prevention of contrast-induced nephropathy in patients with diabetes undergoing coronary angiography and percutaneous coronary interventions: systematic review and meta-analysis","volume":"14","author":"Meregildo-Rodriguez","year":"2023","journal-title":"Front Endocrinol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"10759","DOI":"10.3390\/ijms251910759","article-title":"SGLT2 inhibitors and the risk of contrast-associated nephropathy following angiographic intervention: contradictory concepts and clinical outcomes","volume":"25","author":"Heyman","year":"2024","journal-title":"Int J Mol Sci"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"22937","DOI":"10.1038\/s41598-024-74233-7","article-title":"Short term sodium glucose transport protein 2 inhibitors are associated with post contrast acute kidney injury in patients with diabetes","volume":"14","author":"Zang","year":"2024","journal-title":"Sci Rep"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"e51228","DOI":"10.7759\/cureus.51228","article-title":"Acute kidney injury: definition, management, and promising therapeutic target","volume":"15","author":"Almazmomi","year":"2023","journal-title":"Cureus"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1681\/ASN.0000000000000125","article-title":"Detecting neonatal AKI by serum cystatin C","volume":"34","author":"Xu","year":"2023","journal-title":"J Am Soc Nephrol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.71480\/nmj.v66i3.936","article-title":"NGAL superiority to creatinine in the diagnosis of renal injury in a pediatric tertiary hospital setting","volume":"66","author":"Ohiri","year":"2025","journal-title":"Niger Med J"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s12882-024-03570-6","article-title":"Contrast-induced acute kidney injury: a review of definition, pathogenesis, risk factors, prevention and treatment","volume":"25","author":"Li","year":"2024","journal-title":"BMC Nephrol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"e070561","DOI":"10.1136\/bmjopen-2022-070561","article-title":"Risk factors associated with contrast-associated acute kidney injury in ST-segment elevation myocardial infarction patients: a systematic review and meta-analysis","volume":"13","author":"Ye","year":"2023","journal-title":"BMJ Open"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s12325-024-03036-z","article-title":"Predictors for irreversibility of contrast-induced acute kidney injury in patients with obesity after contrast-enhanced computed tomography coronary angiography","volume":"42","author":"Berezina","year":"2025","journal-title":"Adv Ther"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.iccl.2023.06.007","article-title":"Contrast-associated acute kidney injury: definitions, epidemiology, pathophysiology, and implications","volume":"12","author":"Vemireddy","year":"2023","journal-title":"Interv Cardiol Clin"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1177\/00033197231155610","article-title":"The impact of contrast-associated acute kidney injury on all-cause mortality in older patients after coronary angiography: a 7.5-year follow-up","volume":"75","author":"Guo","year":"2024","journal-title":"Angiology"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.jcin.2021.11.026","article-title":"Long-term clinical impact of contrast-associated acute kidney injury following PCI: an ADAPT-DES substudy","volume":"15","author":"Mohebi","year":"2022","journal-title":"JACC Cardiovasc Interv"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"366","DOI":"10.4103\/hm.HM-D-25-00021","article-title":"Prognostic impact of dynamic evolution in kidney function among patients undergoing elective percutaneous coronary intervention: a prospective cohort study","volume":"9","author":"Lin","year":"2025","journal-title":"Heart Mind"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"288","DOI":"10.2215\/CJN.02600607","article-title":"Renal parenchymal hypoxia, hypoxia adaptation, and the pathogenesis of radiocontrast nephropathy","volume":"3","author":"Heyman","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s40620-018-0498-y","article-title":"Contrast medium induced acute kidney injury: a narrative review","volume":"31","author":"Pistolesi","year":"2018","journal-title":"J Nephrol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.iccl.2020.03.001","article-title":"Pathophysiology of contrast-induced acute kidney injury","volume":"9","author":"Bansal","year":"2020","journal-title":"Interv Cardiol Clin."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1177\/00033197231185445","article-title":"Association between inflammatory biomarkers and contrast-induced acute kidney injury in ACS patients undergoing percutaneous coronary intervention: a cross-sectional study","volume":"75","author":"Yang","year":"2024","journal-title":"Angiology"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"14K","DOI":"10.1016\/j.amjcard.2006.01.020","article-title":"Pathophysiology of contrast-induced nephropathy","volume":"98","author":"Tumlin","year":"2006","journal-title":"Am J Cardiol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.3390\/ijms26072869","article-title":"Biomarkers in contrast-induced nephropathy: advances in early detection, risk assessment, and prevention strategies","volume":"26","author":"Lee","year":"2025","journal-title":"Int J Mol Sci"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"e1081","DOI":"10.23938\/ASSN.1081","article-title":"Biomarkers of oxidative stress and inflammation in contrast-associated acute kidney injury","volume":"47","author":"Stoll","year":"2024","journal-title":"An Sist Sanit Navar"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1161\/CIRCULATIONAHA.124.069568","article-title":"Sodium-glucose cotransporter-2 inhibitors and major adverse cardiovascular outcomes: a SMART-C collaborative Meta-analysis","volume":"149","author":"Patel","year":"2024","journal-title":"Circulation"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"7057","DOI":"10.3390\/ijms25137057","article-title":"The renoprotective mechanisms of sodium-glucose cotransporter-2 inhibitors (SGLT2i)-a narrative review","volume":"25","author":"Iordan","year":"2024","journal-title":"Int J Mol Sci"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"e70233","DOI":"10.1111\/ctr.70233","article-title":"Potential role of SGLT-2 inhibitors in improving allograft function and reducing rejection in kidney transplantation","volume":"39","author":"Demir","year":"2025","journal-title":"Clin Transpl"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3390\/medicina61020202","article-title":"Update on the efficacy and safety of sodium-glucose co-transporter 2 inhibitors in patients with chronic diseases: a systematic review and meta-analysis","volume":"61","author":"Liang","year":"2025","journal-title":"Medicina"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3390\/biom15010039","article-title":"Comparative efficacy and safety of cardio-renoprotective pharmacological interventions in chronic kidney disease: an umbrella review of network meta-analyses and a multicriteria decision analysis","volume":"15","author":"Bellos","year":"2024","journal-title":"Biomolecules"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s40256-024-00684-y","article-title":"Efficacy of chronic use of sodium-glucose co-transporter 2 inhibitors on the prevention of contrast-induced acute kidney injury in patients with type 2 diabetes mellitus following coronary procedures: a systematic review and Meta-analysis","volume":"25","author":"Dimitriadis","year":"2025","journal-title":"Am J Cardiovasc Drugs"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"918167","DOI":"10.3389\/fcvm.2022.918167","article-title":"Contrast-induced acute kidney injury in patients on SGLT2 inhibitors undergoing percutaneous coronary interventions: a propensity-matched analysis","volume":"9","author":"Hua","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"110766","DOI":"10.1016\/j.diabres.2023.110766","article-title":"Impact of SGLT2-inhibitors on contrast-induced acute kidney injury in diabetic patients with acute myocardial infarction with and without chronic kidney disease: insight from SGLT2-I AMI PROTECT registry","volume":"202","author":"Paolisso","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.3390\/jcm13072041","article-title":"Contrast-induced acute kidney injury in patients with heart failure on sodium-glucose cotransporter-2 inhibitors undergoing radiocontrast agent invasive procedures: a propensity-matched analysis","volume":"13","author":"Nardi","year":"2024","journal-title":"J Clin Med"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s13098-023-01107-9","article-title":"The safety of SGLT-2 inhibitors in diabetic patients submitted to elective percutaneous coronary intervention regarding kidney function: SAFE-PCI pilot study","volume":"15","author":"Feitosa","year":"2023","journal-title":"Diabetol Metab Syndr"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1681\/ASN.2022030306","article-title":"Correlates and consequences of an acute change in eGFR in response to the SGLT2 inhibitor Dapagliflozin in patients with CKD","volume":"33","author":"Jongs","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1552539","DOI":"10.3389\/fmed.2025.1552539","article-title":"Effect of sodium-glucose co-transporter 2 inhibitor on contrast-induced acute kidney injury and prognosis in type 2 diabetes patients undergoing percutaneous coronary intervention","volume":"12","author":"Yang","year":"2025","journal-title":"Front Med"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"420","DOI":"10.3390\/ph17040420","article-title":"Acute kidney injury and electrolyte imbalances caused by dapagliflozin short-term use","volume":"17","author":"Lopes","year":"2024","journal-title":"Pharmaceuticals"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1007\/s40620-020-00712-5","article-title":"SGLT2 inhibitor therapy in patients with type-2 diabetes mellitus: is acute kidney injury a concern?","volume":"33","author":"Baker","year":"2020","journal-title":"J Nephrol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1007\/s11255-022-03211-7","article-title":"Acute kidney injury following SGLT2 inhibitors among diabetic patients: a pharmacovigilance study","volume":"54","author":"Chen","year":"2022","journal-title":"Int Urol Nephrol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s40264-017-0602-6","article-title":"Can SGLT2 inhibitors cause acute renal failure? Plausible role for altered glomerular hemodynamics and medullary hypoxia","volume":"41","author":"Szalat","year":"2018","journal-title":"Drug Saf"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"e14890","DOI":"10.14814\/phy2.14890","article-title":"Impact of sodium glucose linked cotransporter-2 inhibition on renal microvascular oxygen tension in a rodent model of diabetes mellitus","volume":"9","author":"Hare","year":"2021","journal-title":"Physiol Rep"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"F227","DOI":"10.1152\/ajprenal.00689.2014","article-title":"Acute SGLT inhibition normalizes O2 tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats","volume":"309","author":"O'Neill","year":"2015","journal-title":"Am J Physiol Renal Physiol"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1080\/0886022X.2020.1801466","article-title":"Biomarker evidence for distal tubular damage but cortical sparing in hospitalized diabetic patients with acute kidney injury (AKI) while on SGLT2 inhibitors","volume":"42","author":"Darawshi","year":"2020","journal-title":"Ren Fail"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41580-020-0227-y","article-title":"Cellular adaptation to hypoxia through hypoxia inducible factors and beyond","volume":"21","author":"Lee","year":"2020","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1007\/s40265-022-01783-3","article-title":"Evolving strategies in the treatment of anaemia in chronic kidney disease: the HIF-prolyl hydroxylase inhibitors","volume":"82","author":"Locatelli","year":"2022","journal-title":"Drugs"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1093\/ndt\/gfs100","article-title":"Cellular adaptive changes in AKI: mitigating renal hypoxic injury","volume":"27","author":"Heyman","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"C661","DOI":"10.1152\/ajpcell.00177.2023","article-title":"Reno- and cardioprotective molecular mechanisms of SGLT2 inhibitors beyond glycemic control: from bedside to bench","volume":"325","author":"Chen","year":"2023","journal-title":"Am J Physiol Cell Physiol"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"e080257","DOI":"10.1136\/bmj-2024-080257","article-title":"Sodium-glucose cotransporter-2 (SGLT-2) inhibitors for adults with chronic kidney disease: a clinical practice guideline","volume":"387","author":"Agarwal","year":"2024","journal-title":"BMJ"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1744473\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T05:25:19Z","timestamp":1765776319000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1744473\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":51,"alternative-id":["10.3389\/fmed.2025.1744473"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1744473","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,15]]},"article-number":"1744473"}}